Non-viral gene therapy solutions for tissue regeneration
Tissues undergo damage due to various factors like disease, injury, ageing and need to be repaired and regenerated. The body is unable to always repair and regenerate tissues. In such cases, an instruction and boost to the body would help in regeneration.
TherageniX uses proprietary technology to deliver genes which can instruct the body to produce relevant proteins or factors that help in tissue regeneration.
📢Click here to view the same video with scientific jargon.
Our Technology and Focus
TherageniX’s virus-free peptide-based technology uses plasmid DNA and engineered peptides to form nanocomplexes that deliver DNA cargo into hard-to-transduce cells. Peptides can be customized to improve transduction while the cargo can be modified to deliver a variety of therapeutic agents.
With bone being the second most transplanted tissue after blood – 4 million grafting procedures are performed annually, along with a projected 45% increase in surgeries by 2030, Â there is a critical demand for more effective treatment options. Bone implants often fail due to rejection, infection, or inadequate regeneration. TherageniX aims to deliver regenerative factor genes, such as BMPs and VEGF, intra-operatively with autologous bone marrow cells to enhance regeneration and reduce donor site trauma. Â Additionally, TherageniX’s product can be combined with existing biomaterials, increasing patient access to this innovative therapy.
TherageniX technology offers several key advantages over existing options
- Enhanced safety
- Higher versatility and lower costs
- Elimination of waiting times
- Accelerated pipeline expansion opportunities
News from TherageniX
Bench to Bedside: A Roadmap for Developing Novel Gene Therapies
TherageniX team – Stefania and Anand, together with our inventor, James Dixon from the University of Nottingham have authored an article on how to translate
TherageniX appoints Regenerative engineering pioneer, Prof. Cato Laurencin to its Scientific Advisory Board
Biomaterials, stem cells and gene therapy expert, and orthopaedic surgeon joins TherageniX’s scientific Advisory Board to advance product development and advise on company strategy. TherageniX
Non-viral gene therapies: GETting growth-factor-based healing right in orthopaedics
Anand Nandakumar (our CEO) and Dr. James Dixon (inventor) wrote an article on the use of non-viral gene therapies for bone regeneration. This has been
TherageniX appoints Professor Ben Ollivere to its Scientific Advisory Board
Experienced Orthopaedic surgeon, researcher, and academic joins TherageniX’s scientific Advisory Board to help accelerate product development. TherageniX (www.theragenix.health) , an early-stage biotechnology company pioneering the
TherageniX is looking for a Scientific Project Manager
Job Title Scientific Project Manager Job Type Fixed-Term 1 year (with possibility of extension), Full-time Hours per week 37.5 per week Location Remote with occasional
TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration
London, UK, and Nottingham, UK, 31 August 2023: TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft
THERAGENIX: SPIN-OUT COMPANY ESTABLISHED TO PROVIDE GENE THERAPY IN BONE REPAIR SURGERY
Our partner, U of N also shared their perspective on the launch of TherageniX, a spin-out company – TherageniX to deliver gene therapy as part of bone repair
INTRODUCING THERAGENIX: TISSUE REGENERATION THROUGH GENES
Disease, injuries and aging can damage body tissues. There is an unmet need for novel therapies to enable tissue repair and regeneration. The use of